event-image

Whilst estrogen receptor positive breast cancer has a targeted treatment strategy, many patients develop resistance, leaving them with no option other than chemotherapy. Now these women have hope!

Dr Theresa Hickey from the Dame Roma Mitchell Cancer Research Laboratories at the University of Adelaide is pioneering vital research to better understand why patients develop therapy resistance in the hopes of crafting new treatment strategies to combat this fatal form of the disease.

“We believe that breast cancer represents a state of hormone imbalance and are exploring whether restoring this balance will be an effective, less toxic way of treating or preventing estrogen receptor positive breast cancer.”

About 75 per cent of all breast cancers are estrogen receptor positive, meaning the cancer cells grow in response to the sex hormone estrogen. These cancers also commonly have other sex hormone receptors, including androgen and progesterone receptors.

“Breast cancers that have all three sex hormone receptors are much more likely to respond to anti-estrogen therapy than those that have estrogen receptor alone. Those that have estrogen receptor and just one other sex hormone receptor lie in between these extremes in terms of therapy response,” Theresa said.

“We know that the major cause of death from breast cancer is resistance to current estrogen receptor target therapies, so through our research we are developing alternative approaches to treat or prevent therapy resistant disease.”

To develop these alternative therapies, Dr Hickey and her team first had to understand the hormonal imbalance that occurs within breast cancer to decipher how to target this with a potential treatment.

“The sex hormones estrogen and androgen are natural antagonists in men and women, and their relative action dictates biological gender and sex differences in the functioning of many body organs.

“The breast is an excellent example of sex hormone antagonism as breasts develop in women due to a predominance of estrogen action and do not develop in men due to a predominance of androgen action.

“Since estrogen receptor positive breast cancer is driven by abnormal estrogen activity, we suspect the androgen receptor is not able to play its normal role to keep the balance in check.

“We aim, through a new therapy, to reawaken androgen receptor activity in estrogen receptor positive breast cancers to stimulate its ability to control the actions of estrogen and in turn prevent breast cancer from forming or treat it once it has developed.”

Continuing to explore the role of these receptors in estrogen driven breast cancer, Dr Hickey’s research will open up avenues for repurposing drugs currently in use for other diseases in the hopes of beating the most aggressive breast cancers affecting our loved ones.

Donate today to support more research like Dr Hickey’s.

you may also like...

Research Saved a Young Mum’s Life

It was a pain in her right breast, like that of a torn muscle, which led young mother Kate Shields to a breast cancer diagnosis that she never saw coming. In January last year the 38-year-old mother was diagnosed with aggressive hormonal breast cancer. read more

Building Breast Cancer Knowledge from Around the Globe

Thanks to your generous support, each year The Hospital Research Foundation (THRF) funds travel grants to support researchers and students to attend various conferences and meetings relevant to their field of research, having the opportunity to network with fellow researchers around the globe. read more

The Fight to Beat Triple Negative Breast Cancer

Head of the Cell Signalling Laboratory at the Centre for Cancer Biology (CCB), Associate Professor Yeesim Khew-Goodall is leading a crucial research project focused on overcoming resistance to cancer therapy, particularly in triple negative breast cancer. read more

Research Hope for Triple Negative Breast Cancer

Can you imagine being diagnosed with a type of cancer that has no targeted treatments? This could change thanks to researchers at the Basil Hetzel Institute for Translational Health Research (BHI) who are working hard to investigate possible treatments for triple negative breast cancer. read more

New Hope for Metastatic Breast Cancer

Thanks to the incredible generosity of one of our very special donors, Dr Margaret Elcombe, our researchers have been awarded the Elcombe Pre-Clinical Project Grant to pursue a promising new treatment avenue for breast cancer that has spread which if successful would be far less toxic than current treatments. read more